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Abstract
Background: To report early and long-term outcomes of patients undergoing minimally invasive mitral valve surgery
(MIMVS) through right mini-thoracotomy (RT) over a 10-year period.
Methods: From September 2003 to December 2013, a total of 1604 consecutive patients underwent MIMVS through RT.
Results: The mean age was 63 ± 13 years, 770 (48 %) patients were female and 218 (13.6 %) had previous
cardiac operations. The most predominant pathology was degenerative disease (70 %), followed by functional mitral
valve regurgitation (12 %), rheumatic disease (9.4 %), endocarditis (5 %) and prosthetic dysfunction (3.2 %). Mitral valve
repair was performed in 1137 (71 %) patients and 476 (29 %) had mitral valve replacement. Direct aortic cannulation
was achieved in 1325 (83 %) patients. Among patients with degenerative disease candidate for repair (n = 958), rate of
mitral valve repair was 95 %. Repair techniques included annuloplasty (95 %), leafleat resection (63 %), neochordae
implantation (16 %) and sliding plasty (11 %). Concomitant procedures included tricuspid valve repair (14.6 %), atrial
fibrillation ablation (9.5 %) and atrial septal defect closure (3.2 %). Overall in-hospital mortality was 1.1 %. Thirty-four
patients (2.1 %) had conversion to sternotomy. Incidence of stroke was 2 %. Overall survival at 10 years was 88 ± 2 %.
Freedom from reoperation at 10 years was 94 ± 2 % for repair and 80 ± 6 % for replacement. Freedom from recurrent
mitral regurgitation >3+ at 10 years was 90 ± 3 %.
Conclusions: Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality
and morbidity, high rate of mitral valve repair and excellent late results.
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Background
Mitral valve surgery using conventional full sternotomy
(FS) is the conventional approach for the treatment of
the mitral valve disease. Despite this procedure has
shown excellent postoperative outcomes, in the last two
decades minimally invasive mitral valve surgery
(MIMVS) has gained consensus among surgeons as it
has provided greater patients satisfaction, maintaining
the same quality and safety of the standard mitral valve
surgery approach [1, 2].
According to a statement from the American Heart
Association, the term “minimally invasive” refers to a
small chest wall incision that does not include a FS [3].
The most common MIMVS approach is the right thora-
cotomy (RT) followed by the partial sternotomy. Com-
pared with conventional surgery, MIMVS has been
shown excellent results in terms of mortality, morbid-
ities and pain, providing shorter hospital stay, faster re-
covery and return to normal activities which translate
into less use of rehabilitation resources and healthcare
costs [4–10]. Although these benefits, criticisms have
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been raised as MIMVS is technically more complex, re-
quires a distinct learning curve and is associated with
higher incidence of neurological events, aortic dissec-
tion, groin complications and higher rate of mitral valve
replacement instead of mitral valve repair [5, 11]. Since
2003, we started our MIMVS program and after few
years, RT approach has become the standard approach
for the treatment of mitral valve disease. The aim of our
study is to report early and long-term outcomes of con-
secutive patients who had undergone mitral valve sur-
gery using RT during a 10-year period.
Methods
Patient selection and data collection
A retrospective, observational study was undertaken of
prospectively collected data in 1800 consecutive patients
undergoing mitral valve surgery, of which 1604 under-
went MIMVS through RT between September 2003 and
December 2013 (Fig. 1). One hundred and ninety-six
procedures were performed in sternotomy. The main
reason for performing a sternotomy approach was the
selection patient for the learning curve, and in case of
very poor left ventricular ejection fraction, strong pleural
adhesions, severe chronic obstructive pulmonary disease
and active endocarditis with abscess involving the mitro-
aortic continuity. The ethical committee approved the
study, and individual consent was waived. The data col-
lection form was entered in a local database and in-
cluded three sections completed consecutively by the
cardiac surgeons, anaesthetists and perfusionists in-
volved in the care of the patients.
The main outcomes investigated were early and late
mortality, perioperative complications, and freedom
from MR recurrence and reoperation.
Early mortality was defined as any death occurring
within 30 days of operation or before discharge from the
hospital. Stroke was defined as any new focal or global
neurological deficit lasting more than 24 h, and were
confirmed whenever possible by neurologists and neuro-
radiologists. Postoperative stroke was diagnosed if evi-
dence was found of a new neurologic deficit with
morphologic substrate confirmed by computed tomog-
raphy or nuclear magnetic resonance imaging.
Acute kidney injury was defined as postoperative cre-
atinine increase of 1+ mg/dl or requirement of haemodi-
alysis. Perioperative myocardial infarction was defined as
maximum creatine kinase MB elevation three times
above the upper normal level and new Q waves >0.04 ms
and/or reduction in R waves >25 % in at least two con-
tiguous leads in the electrocardiogram or the proof of
new wall motion disturbances in the echocardiogram.
Pulmonary complications included ventilation failure,
reintubation and tracheostomy.
All patients were seen 8 to 12 weeks postoperatively
and thereafter were contacted for follow-up data. The
median follow-up time was 32 months (interquartile
range 9–59 months) and the follow-up data were 96.6 %
complete.
All patients had a preoperative transthoracic echocar-
diography as well as at discharge. The severity of mitral
regurgitation was graded following the European Society
of Cardiology and the European Association for Cardio-
Thoracic Surgery recommendations [12]. Echocardio-
graphic follow-up consisted of those patients who
survived and had postoperative echocardiogram more
than 6 months (812/1492, 52 %) at a median of
15 months (IQR 6–51) after surgery. Recurrent MR was
defined as moderate or severe on a 4-point grade: trivial,
1 of 4; mild, 2 of 4; moderate, 3 of 4; and severe, 4 of 4.
Surgical technique
The standardized surgical approach for MIMVS has
been reported elsewhere [13]. Briefly, MIMVS by a way
of right anterior thoracotomy was performed through a
5–7 cm skin incision placed at 3th or 4th intercostal
space. After incision a soft tissue retractor is inserted
and the intercostal space is gently spread with a
retractor. Two trocars are inserted in the thorax to allow
positioning of a ventricular vent, CO2 insufflator, camera
device and pericardial stay sutures. Whereas at the be-
ginning of our experience the approach involved retro-
grade arterial perfusion and balloon endoclamping, the
procedure has evolved to a technique with ascending
aorta cannulation, long femoral venous cannula drain-
age, and direct transthoracic aortic clamping. Specific-
ally, direct aortic cannulation was performed using
Easyflow (Sorin, Salluggia, Italy) or Straightshot (Edwards
Lifesciences, Irvine, Calif) cannulas. Biomedicus single
stage (Medtronic, Minneapolis, Minn) or RAP single 2
stage cannulas (Estech) were inserted through the femoral
vein into the right atrium and the correct position was
Fig. 1 Number of minimally invasive mitral valve procedures in
10-year activity
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achieved with the Seldinger technique under transesopha-
geal echocardiographic guidance. In case of mitral and tri-
cuspid valve surgery, a single 2 stage cannula (RAP,
Estech) was used as it allows to drain simultaneously the
superior and inferior venae cavae. After vacuum-assisted
cardiopulmonary bypass ( −40 to −60 mmHg) was estab-
lished, the patients were cooled to 34 C°. the ascending
aorta was clamped with the Cygnet crossclamp (ovare sur-
gical System, Cupertino, Calif) or with the aortic Glauber
clamp (Cardiomedical GmbH, Langenhagen, Germany;
distributed by sorin, Salluggia, Italy) and antegrade cold
crystalloid or warm blood cardioplegia is delivered directly
into the ascending aorta by a needle vent catheter.
The mitral valve is approached with a traditional left
paraseptal atriotomy and exposed using a specially de-
signed atrial retractor held by a mechanical harm inserted
through a right parasternal port. Mitral valve procedures
were performed under a combination of direct vision and
thoracoscopic assistance. The surgical steps that we were
unable to perform under direct vision were performed
with video assistance, such as placement of sutures on the
anterior annulus of the mitral valve, or at the level of the
posterior medial commissures. In the setting of degenera-
tive mitral valve disease, mitral valve repair was the first
approach for the degenerative mitral valve repair; mitral
valve replacement was commonly used in presence of se-
vere annulus and/or leaflet calcifications and patients
older than 80 with complex complex repair. All patients
received an accurate intraoperative transoesophageal
echocardiogram before and after weaning from cardiopul-
monary bypass machine. In patients who had an attempt
to repair, our policy is to replace the mitral valve if a) at
the hydrostatic saline test after several attempts, there is
still some degrees of mitral regurgitation, b) the surface of
coaptation is not enough to guarantee a long durability, c)
at intraoperative echo, there is more than mild mitral
regurgitation.
Eight surgeons contributed to this series, with 2 of
them (MG, MS) performing 59.2 % of the operations.
Statistical analysis
Continuous data were expressed as mean ± standard de-
viation or median with the interquartile range and cat-
egorical data as percentages. Cumulative survival was
evaluated with the Kaplan–Meier method. All reported
P values are two-sided, and P values of <0.05 were con-
sidered to indicate statistical significance. All statistical
analyses were performed with SPSS 22.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Baseline characteristics are listed in Table 1. The
mean age was 63 ± 13 years, 770 (48 %) patients were
female and 215 (13.4 %) had previous cardiac
operations. The mean body mass index was 25 ± 4.8
Kg/m2. The mostpredominant pathology was degen-
erative disease (n = 1114, 70 %), followed by func-
tional mitral valve regurgitation (n = 191, 12 %),
rheumatic disease (n = 151, 9.4 %), endocarditis (n = 80,
5 %) and prosthetic dysfunction (3.2 %), Table 2. Mitral
valve repair was performed in 1137 (71 %) patients and
476 (29 %) had mitral valve replacement (Table 2). Direct
aortic cannulation was achieved in 1325 (83 %) patients.
In 1432 (89.9 %) of cases, the aorta was cross-clamped; in
130 (8.1 %) an endo-aortic balloon was used, and in 43
(2.7 %), operations were performed in beating heart or
ventricular fibrillation.
Median CBP time was 131 (IQR 109–162) min, and
median cross-clamp time was 88 min (IQR 69–112).
Concomitant procedures included tricuspid valve repair
(n = 234, 14.6 %), atrial fibrillation ablation (n = 152,
9.5 %) and atrial septal defect closure (n = 51, 3.2 %).
Early outcomes
Overall in-hospital mortality was 1.1 % (n = 19, predicted
median EuroSCORE 6 %, interquartile range 3–14 %).
Thirty-four patients (2.1 %) had conversion to sternot-
omy either because of bleeding (21, 1.3 %), strong adhe-
sions (9, 0.5 %), aortic dissection due to the use of
endoclamp (4, 0.25 %); 23 (1.4 %) patients required an
IABP. Incidence of stroke, transient ischemic attack and
acute renal failure requiring dialysis was 2 % (n = 32),
0.25 % (n = 4) and 1.3 % (n = 21). Twenty-three patients
(1.4 %) had myocardial infarction, 41 patients (2.5 %)
had pulmonary complications and rate of pacemaker im-
plantation was 3.3 % (n = 53). Mean ICU stay was 1 day
(IQR 1.0–1.0), and mean ward stay was 6 days. 951
(59.3 %) patients were discharged home. Postoperative
outcomes are reported in Table 3.
Mitral valve repair
Out of 1210 candidates for valve repair, 1137 were ef-
fectively repaired (94 %), while 73 (6 %) required re-
placement after a repair attempt. Repair techniques
included annuloplasty (95 %), either alone (264/1137,
23.2 %) or with another repair technique (814/1137,
71.6 %), including leaflet resection (63 %), neochordae
implantation (16 %), and sliding plasty (11 %). For the
1137 patients that were effectively repaired, 19 (1.7 %)
required conversion to full sternotomy and 29 (2.5 %)
had to be reoperated for evidence, at pre-discharge
echocardiography, of significant mitral regurgitation: in
12 cases the valve was replaced; in the remaining 17
(59 %) the valve was effectively re-repaired.
After repair, residual MR at discharge was very low
(no MR: 803 (72,6 %), trivial: 264 (23 %), mild: 38
(3.3 %), moderate MR: 1 (0.08 %).
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Out of 1114 patients affected by a degenerative mitral
valve disease, 958 (86 %) of them were candidates for re-
pair; successful repair rate was 94.7 % (907/958). Out of
the remaining 156 patients, 80 were not deemed amen-
able to repair because of previous operation on the valve
(n = 32) or severe calcifications (involving annulus and/
or leaflets n = 48). In the remaining 76 cases, the learn-
ing curve was considered the main cause.
Mitral valve replacement
Mitral valve replacement was performed in 467 patients.
The predominant pathologies were degenerative (n = 207,
44.3 %) and rheumatic (134, 28.7 %). Other entities were
functional regurgitation (n = 36), ischemic regurgitation
(n = 19), active (n = 24) and inactive (n = 10) endocarditis,
prosthesis dysfunction (n = 28), congenital valve disease
(n = 2), and other (n = 7). Mechanical and biological pros-
thesis was implanted in 224 (48 %) and 243 (52 %), re-
spectively. As previously stated, 73 replacements were
failed repairs.
Late outcomes
Median follow-up time was 32 months (IQR 9–59) and
was 96.6 % complete. At follow-up, 114 patients were
dead: 61 patients were MVR and 53 were mitral valve
repair.
Survival
Overall 1-, 5- and 10-year survival were 96.3 ± 0.5 %,
88.9 ± 1.1 %, and 84.5 ± 1.8 % respectively, Fig. 2a. Spe-
cifically, survival after repair at 1-, 5- and 10-years was
98.5 ± 0.4 %, 91.9 ± 1.2 %, and 88.0 ± 2.1 % respectively.
Survival after replacement at 1-, 5- and 10-years was 91.
±1.4 %, 81.3 ± 2.5 %, and 76.2 ± 3.4 % respectively,
Fig. 2b.
In the setting of degenerative mitral valve diseased,
overall 1-, 5-, and 10-year survival was 98.1 ± 0.4 %, 91.8
± 1.2 %, and 88.1 ± 1.9 % respectively, Fig. 2c. Specific-
ally, rate of survival after mitral valve repair was 99.2 ±
0.3 % at 1 year, 93.5 ± 1.3 % at 5 years and 90.1 ± 2 % at
10 years, whereas survival after mitral valve replacement
was 92.7 ± 1.8 % at 1 year, 84.4 ± 3.2 % at 5 year, and
79.3 ± 4.6 % at 10 year, respectively Fig. 2d. Overall 1-, 5-
and 10-year survival were 94.3 ± 1.7 %, 83.8 ± 3.8 % and
81.2 ± 4.5 % for patients who received a mechanical valve
Table 1 Baseline characteristics
Variable Overall Repair Replacement
N = 1604 N = 1137 N = 467
Age, years (mean ± SD) 63 ± 13 61 ± 13 67 ± 11
Female sex, N (%) 770 (47.0) 493 (43.4) 277 (59.3)
Hypertension, N (%) 940 (57.3) 639 (56.2) 301 (58.6)
Diabetes, N (%) 167 (10.2) 97 (8.5) 70 (15.0)
COPD, N (%) 155 (9.5) 96 (8.4) 59 (12.6)
Previous valve operations, N (%) 156 (9.7) 37 (3.3) 119 (25.5)
Previous CABG, N (%) 59 (3.7) 30 (2.6) 29 (6.2)
Preop AF, N (%) 545 (33.9) 312 (27.4) 233 (49.9)
NYHA III-IV, N (%) 538 (33.5) 314 (27.6) 224 (48.0)
Preop EF %(mean ± SD) 57.6 ± 9.3 58.8 ± 8.6 54.7 ± 10.2
Pulmomary Hypertension (≥60 mmHg) 152 (9.5) 84 (7.4) 68 (14.5)




N = 1604 N = 1137 N = 467
Degenerative 1114 (69.5 %) 907 (81.5 %) 207 (18.5 %)
Functional 191 (11.9 %) 136 (71.2 %) 55 (28.8 %)
Reumathic 151 (9.4 %) 17 (11.2 %) 134 (88.8 %)
Endocarditis 80 (5.0 %) 46 (57.5 %) 34 (42.5 %)
Prosthesis dysfunction 38 (2.4 %) 10 (26.3 %) 28 (73.7 %)
Miscellaneous 30 (1.9 %) 21 (70 %) 9 (30 %)
Table 3 Early outcomes
Variable Overall Repair Replacement
(N = 1604) N = 1137 N = 467
In hospital Mortality 19 (1.2 %) 4 (0.4 %) 15 (3.2 %)
Stroke 32 (2 %) 20 (1.8 %) 12 (2.6 %)
RF requiring dialysis 21 (1.3 %) 11 (1 %) 10 (2.1 %)
New onset postoperative AF 253 (15.8 %) 171 (15.0 %) 82 (17.6 %)
Reoperation for bleeding 78 (4.9 %) 48 (4.2 %) 30 (6.4 %)
Ventilation time, h 7 (5–11) 7 (5–10) 9 (6–15)
ICU stay, day 1 (1–1) 1 (1–1) 1 (1–1)
Ward stay, day 5 (4–7) 5 (4–6) 5 (4–7)
Discharged Home 951 (59.3 %) 769 (67.6 %) 182 (39.0 %)
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and 88.3 ± 2.2 %, 83.8 ± 3.8 % and 81.2 ± 4.5 % for those
who had a bioprosthesis.
Reoperation
Overall freedom from reoperation was 98.6 ± 0.3 %,
94.7 ± 0.7 %, and 91.1 ± 1.7 % at 1-, 5-, and 10-years,
respectively, Fig. 3a. After mitral valve repair, freedom
from reoperation at 1-, 5- and 10-years was 98.4 ±
0.4 %, 94.8 ± 0.9 % and 93.6 ± 1.1 %, respectively.
Freedom from reoperation after replacement at 1-, 5-
and 10-years was 98.6 ± 0.6 %, 94.5 ± 1.6 % and 83.9 ±
5.5 % respectively, Fig. 3b.
In the setting of degenerative mitral valve disease,
overall 1-, 5-, and 10-year freedom from repair was
99 ± 0.3 %, 96.3 ± 0.8 %, and 93.9 ± 1.3 % respectively,
Fig. 3c. Specifically, rate of freedom from reoperation
after mitral valve repair was 98.9 ± 0.3 % at 1 year,
Fig 2 a: Overall survival; b: overall survival in mitral valve repair and replacement; c: overall survival in patients undergoing mitral valve surgery for
degenerative mitral valve disease; d: survival in patients undergoing mitral valve repair and replacement for degenerative mitral valve disease
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96.4 ± 0.8 % at 5 years and 95.4. ± 1.1 % at 10 years,
whereas aftermitral valve replacement was 99.5 ±
0.5 % at 1 year, 95.8 ± 2.3 % at 5 year, and 91.3 ±
5.1 % at 10 year, respectively Fig. 3d.
Recurrent mitral regurgitation
Freedom from recurrent mitral regurgitation was 99 ±
0.4 % at 1 year, 95 % ± 1.3 % at 5 years and 86.6 % ± 3.8,
Fig. 4a. In the setting of patients undergoing mitral valve
repair for degenerative mitral valve disease, freedom
from recurrent MR after 1, 5 and 10- years was 99 ±
0.6 % and 93.6 % ± 1.9 %, 86 % ± 4.9 %, Fig. 4b.
Discussion
We demonstrated that MIMVS through RT is a safe
procedure, associated with excellent postoperative out-
comes, short hospital length of stay and outstanding
long-term results. Specifically, overall in-hospital mortal-
ity was 1.1 % lower than the recent mortality rate re-
ported in the Society of Thoracic Surgeons Database
and the low incidence of postoperative complications as
Fig 3 a: Overall freedom from reoperation; b: overall freedom from reoperation in mitral valve repair and replacement; c: overall freedom from
reoperation in patients undergoing mitral valve surgery for degenerative mitral valve disease; d: overall freedom from reoperation in patients undergoing
mitral valve repair and replacement for degenerative mitral valve disease
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Fig. 4 a: Overall freedom from recurrent MR; b: freedom form recurrent MR in patients undergoing undergoing mitral valve repair for degenerative mitral
valve disease
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well as the high long-term survival, highlight the safety
of the this procedure in all settings of mitral valve dis-
ease [1]. Finally, in the setting of all mitral valve repair
success rate at discharge was 93 %, with a freedom from
reoperation of 94 % at 10 years. Similar results were
found for the patients undergoing mitral valve repair for
degenerative mitral valve disease.
MIMVS has been shown to decrease postoperative
complications, providing fast recovery, shorter hospital
length of stay, less pain, better aesthetic appearance and
consequently less use of hospital resources [8]. In 2010,
the consensus statement of international society of min-
imally invasive cardiothoracic surgery (ISMICS) con-
cluded that MIMAVS may be an alternative to
conventional mitral valve surgery, given that there was
comparable short term and long term mortality, compar-
able in-hospital morbidity (renal, pulmonary, cardiac
complications, pain perception and readmissions), re-
duced sternal complications, transfusions, postoperative
AF, duration of ventilation and ICU and hospital length
of stay [5]. Similar results were described by the Society
of Thoracic Surgeons of the adult cardiac surgery data-
base as well as by several meta-analyses confirming the
main points of the aforementioned consensus statement
[4, 6–8, 14]. Our results are in line with the current lit-
erature; however, despite these excellent outcomes,
many criticism still remain regarding MIMVS as it is
technically more complex, requires a distinct learning
curve (prolonged cross-clamp and cardiopulmonary by-
pass times) and is supposedly associated with higher in-
cidence of neurological events, aortic dissection, groin
complications and higher rate of mitral valve replace-
ment instead of mitral valve repair [5, 11]. Some authors
argue that limited exposure may lead to insufficient de-
airing and thus an increase risk in neurologic events
[14]. We believe that our standard technique, with cen-
tral cannulation and direct aortic cross-clamping is as
safe as sternotomy in terms of neurological events. We
report a 2 % incidence of postoperative stroke and simi-
lar results have been reached by others [10, 15–17]. It
has been shown that the incidence of stroke does not
seem to depend on the surgical access [8, 16], but rather
on the choice of endo-clamp and peripheral vessel can-
nulation [4, 17, 18]. Previously, we demonstrated that
the use of retrograde perfusion is associated 4-fold in-
crease in stroke and postoperative delirium when com-
pared to anterograde perfusion. We strongly believe in
antegrade perfusion as it is more physiological, reduces
neurological events and avoid the morbidities related the
femoral arterial cannulation in terms of pseudoaneurism
and wound dehiscence. In addition, the use of flexible
cannulae in ascending aorta e direct cross clamp has
abolished the problem of aortic dissection, described in
previous studies [4–6]. In our series, two patients (0.1 %)
experienced aortic dissection with the use of endoaortic
ballon occlusion. It has been suggested that limited ex-
posure may compromise probability of mitral valve re-
pair when performing MIMVS. Overall, data from STS
database and from the Euro Heart Survey indicate that
the rate of valve repair in the US and Europe was 41 and
46.5 % respectively [19, 20]. Recently, Gammie reports a
67 % repair rate through median sternotomy and 85 %
repair rate through minimally invasive access [14]. Many
series have been published so far documenting excellent
MIMVS repair rates (overall 81.2 %, on intention-to-
repair basis 98.4 %), even in the setting of Barlow’s dis-
ease (94.5 and 100 %) [9, 21, 22]. We report 94 % repair
rate of valves that were deemed amenable to repair and
94.7 % in the setting of degenerative valve disease; we
are more keen to attribute repair failures to the com-
plexity of the underlying disease rather than to insuffi-
cient exposure. In our series, low residual MR at
discharge and outstanding freedom from reoperation in-
dicate excellent standards of repair, in line with other
studies, once again confirming that access through mini-
thoracotomy does not interfere with quality and durabil-
ity of valve repair [8, 9]. Finally, regarding the learning
curve, a cross sectional survey on MIMVS concluded
that at least more than 20 cases are required to gain fa-
miliarity with this procedure and at least one case needs
to be performed per week to maintain proficiency [23].
Since 2005, in our institution, MIMVS has become the
standard approach for the treatment of mitral valve dis-
ease. Therefore, due to the low numbers of standard ster-
notomy mitral procedures we have been forced to
introduce young surgeons to mitral valve surgery directly
through a minimally invasive approach. Recently a
CUSUM analysis performed on seven surgeons has shown
that MIMVS can be safely performed with low morbidity
and mortality, even in mitral valve repair [24, 25].
The main limitation of this study is its retrospective
nature; however our database is prospectively compiled.
Although we reported excellent long-term results, echo-
cardiographic data were not available for all patients. No
information has been recorded regarding the aetiology
of perioperative myocardial infarction as well as no in-
formation has been reported regarding the cause of late
mortality. Finally we did not have the possibility to com-
pare our series with a control group, as since the 2005
MIMVS is our standard approach, and patients demand
less invasive procedures. Nevertheless a well-designed
study with appropriate sample size is required to validate
the advantages of MIMVS.
Conclusions
Minimally invasive mitral valve surgery is a safe and re-
producible approach associated with low mortality and
Glauber et al. Journal of Cardiothoracic Surgery  (2015) 10:181 Page 8 of 9
morbidity, high rate of mitral valve repair and excellent
late results.
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